Shareholder Update March 2011

Mar 29th, 2011

 

In this issue:

› Enrolment completed for Phase2 study of VivaGel® for treatment of BV

› Strengthening shareholderbase – new domestic and European investors

› Broad appeal of SPL’sdendrimer technology platform – agrochemicals and drug delivery

› Starpharma’s performance vs the market

 

Download: Shareholder Update: March 2011 ( pdf file, 530kb)


Read More

Completes Enrolment for Phase 2 Study of VivaGel for Treatment of BV

Mar 23rd, 2011

Starpharma today announced it had completed enrolment and all patient follow-up visits in its phase 2 study of VivaGel® for the treatment of bacterial vaginosis (BV).

This study investigated the effectiveness of VivaGel® administered once daily for seven days in the treatment of BV and enrolled 132 participants in the US. Data is now being processed and results will be available in the second quarter of this year.

Read More

Starpharma presents at ASX Emerging Growth Conference, London

Mar 10th, 2011

Starpharma is today presenting at the ASX Emerging Growth conference in London. 

More than 150 institutional fund managers are confirmed for the event.  Starpharma is one of 18 companies participating in this invitation only event, and one of only two healthcare companies. Mesoblast is the other.  

 

Presentation: SPL presents at ASX Emerging Growth Conference ( pdf file, 2MB)

Read More

Starpharma to expand agricultural program through $250,000 funding

Mar 3rd, 2011

Starpharma has been awarded $250,000 funding to enhance agrochemicals using its Priostar® dendrimers. The funding as part of the Victorian Government’s Small Technologies Industry Uptake Program (STIUP), will allow Starpharma to expand its Melbourne-based agricultural programs, further enhancing the commercial prospects of promising candidates. 

Read More

Starpharma interim report and half-year financial results

Feb 21st, 2011

Starpharma released its interim report and financial results for the half-year ended 31 December 2010.

 

Financial Results

  • Cash position at 31 December 2010 $19.7M
  • Net cash burn for the half-year $3.1M
  • Operating cash outflows for the half-year $3.75M
  • Reported loss $4.2M.
Read More

Quarterly Cashflow Report - December 2010

Jan 31st, 2011

The cash balance at 31 December 2010 was $19.7m compared to $22.8m at 30 June 2010. The Operating & Investing cash outflow of $1.5m for the quarter includes costs of the phase 2 bacterial vaginosis (BV) program.  Progress with the Phase 2 BV acute-treatment study for VivaGel®, which commenced in July 2010 has been pleasing, with 90% of patients (119 from a total of 132) now enrolled.

Read More

The Bioshares Top 10 Picks for 2011

Jan 14th, 2011

Abstract: Starpharma is carving up and carving out in as many ways as possible product and application opportunities from its dendrimer chemistry platform. Dendrimers are synthetic, branch like chemical structures that can be engineered very precisely. The addition of smaller functional groups on the periphery or even with the greater structure is what makes the chemistry so versatile.

 

Download: Bioshares Issue 392 ( pdf file, 45kb)

Read More

Results of Annual General Meeting 2010

Dec 11th, 2010

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise that details of the resolutions and the proxies received in respect of each resolution considered by the Starpharma Holdings Limited Annual General Meeting are set out in the attached proxy summary. 


Read More

AGM 2010 Chairman's Address & CEO Presentation

Nov 11th, 2010

View the Chairman's address and CEO's presentations from the 2010 Annual General Meeting held on 11 November 2010.

AGM 2010 Chairman & CEO's Presentation ( pdf file, 1012kb)


Read More

Starpharma's Partner SSL acquired by Reckitt Benckiser

Nov 4th, 2010

Reckitt Benckiser has announced that it has completed its £2.5bn acquisition of SSL after gaining approval from more than 85% of SSL's shareholders by last Friday.  As a result, SSL is now formally part of Reckitt Benckiser and its leading global condom brand Durex will be added to Reckitt’s portfolio of health and personal care “Powerbrands” which include Nurofen, Strepsils and Clearasil.

Read More

Quarterly Cashflow Report - September 2010

Oct 25th, 2010

The cash balance at 30 September 2010 was $20.2m.  The Operating & Investing cash outflow of $2.4m for the quarter includes the set-up and upfront costs of the phase 2 bacterial vaginosis study for VivaGel® commenced in July.

Read More

Starpharma presents at ASX Small to Mid Caps conference, Hong Kong

Oct 20th, 2010

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is one of 20 Australian companies, and one of only two Biotechs, selected to present at the third annual ASX Small to Mid Caps conference in Hong Kong. The ASX Hong Kong conference is part of a series of international investor events designed to showcase emerging Australian small and mid-cap listed companies to investors in Asia, Europe and the US.

Watch the presentation

Read More